Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

  • Moderna Inc MRNA reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90.
  • The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion.
  • Product sales were $6.9 billion from sales of 297 million doses of the Company's COVID-19 vaccine, compared to $200 million in Q4 FY20 from 13 million doses. 
  • Operating income came in at $5.41 billion compared to a loss of $(275) million.
  • Moderna held cash and equivalents of $17.6 billion in Q4.
  • Related: Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs.
  • Share Buyback: The Board of Directors has authorized a new share repurchase program for $3 billion.
  • Outlook: Moderna has signed 2022 Advanced Purchase Agreements for product sales of approximately $19 billion and roughly $3 billion in options, including for any potential updated COVID-19 vaccine booster candidates. 
  • Moderna believes that the SARS-CoV-2 virus will evolve to an endemic phase in 2022 and hence expects sales to be larger in 2H of 2022 than in 1H.
  • Price Action: MRNA shares are down 5.05% at $128.88 during the premarket session on the last check Thursday.
  • Photo by mufidpwt via Pixaby
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!